Maurits F. J. M. Vissers

<scp>LRRK2</scp> Inhibition by <scp>BIIB122</scp> in Healthy Participants and Patients with Parkinson's Disease

Danna Jennings, Sarah Huntwork‐Rodriguez, Maurits F. J. M. Vissers et al. · Movement Disorders · 2023 · 97 citations · Full text

Safety, pharmacokinetics and target engagement of novel <scp>RIPK1</scp> inhibitor <scp>SAR443060</scp> (<scp>DNL747</scp>) for neurodegenerative disorders: Randomized, <scp>placebo‐controlled</scp>, <scp>double‐blind</scp> phase I/Ib studies in healthy subjects and patients

Maurits F. J. M. Vissers, Jules A. A. C. Heuberger, Geert Jan Groeneveld et al. · Clinical and Translational Science · 2022 · 84 citations · Full text

Target engagement and immunogenicity of an active immunotherapeutic targeting pathological α-synuclein: a phase 1 placebo-controlled trial

Pepijn Eijsvogel, Pinaki Misra, Luis Concha‐Marambio et al. · Nature Medicine · 2024 · 27 citations · Full text

Pathological α-Synuclein, Immunology, Pathology +21

A <scp>leucine‐rich</scp> repeat kinase 2 (<scp>LRRK2</scp>) pathway biomarker characterization study in patients with Parkinson's disease with and without <scp>LRRK2</scp> mutations and healthy controls

Maurits F. J. M. Vissers, Matthew D. Troyer, Eva Thijssen et al. · Clinical and Translational Science · 2023 · 12 citations · Full text

Viral clearance, pharmacokinetics and tolerability of ensovibep in patients with mild to moderate COVID‐19: A phase 2a, open‐label, single‐dose escalation study

Manon L. M. Prins, Johan L. van der Plas, Maurits F. J. M. Vissers et al. · British Journal of Clinical Pharmacology · 2022 · 10 citations · Full text